Deproteynyzyrovann y hemoderyvat blood of lambs | Actovegin injection 40 mg / ml ampoules 5 ml 5 pcs.

Latin name

ACTOVEGIN



release form injection solution

Packing

5 ampoules of 5 ml.

Pharmacological action

Pharmacotherapeutic group:

tissue regeneration stimulator

ATC code:

B06AB

Pharmacological action

Pharmacodynamics

Antihypoxant. Actovegin® is a hemoderivative, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).

Positively affects the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and a decrease in the formation of lactate), thus possessing an antihypoxic effect that begins to appear at the latest 30 minutes after parenteral administration and reaches its maximum after an average of 3 hours (2-6 hours). Actovegin® increases the concentration of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.

The effect of Actovegin® on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of transport and oxidation of glucose, are significant in the treatment of diabetic polyneuropathy (DPN). In patients with diabetes mellitus and diabetic polyneuropathy Actovegin® reliably reduces the symptoms of polyneuropathy (stitching, burning sensation, parasthesia, numbness in the lower extremities) Sensitivity disorders are objectively reduced, and patients' mental well-being improves.

Pharmacokinetics

Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of Actovegin®, since it consists only of physiological components that are usually present in the body.

To date, there has been no decrease in the pharmacological effect of hemoderivatives in patients with altered pharmacokinetics (for example, liver or kidney failure, metabolic changes associated with old age, as well as metabolic characteristics in newborns)

Indications

Metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury).

Peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers) diabetic polyneuropathy

Wound healing (ulcers of various etiologies, burns, trophic disorders (pressure sores) disruption of wound healing processes).

Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy

Contraindications

Hypersensitivity to the drug Actovegin or similar drugs, decompensated heart failure, pulmonary edema, oliguria, anuria, fluid retention in the body.

Precautions: hyperchloremia, hypernatremia.

Use during pregnancy and lactation

Use of the drug in pregnant women did not cause a negative effect on the mother or fetus.

However, when used in pregnant women, the potential risk to the fetus must be considered.

Composition of

1 ampoule contains:

active substance:

Actovegin® concentrate (in terms of dry deproteinized calf blood hemoderivative) 1) - 200.0 mg

excipient:

water for injection - up to 5 ml.

Dosage and administration

Depending on the severity of the clinical picture, the initial dose is 10-20 ml / day intravenously or intraarterially, further 5 ml intravenously or 5 ml intramuscularly.

Metabolic and vascular disorders of the brain: at the beginning of treatment, 10 ml intravenously daily for two weeks, then 5-10 ml intravenously 3-4 times a week for at least 2 weeks.

Ischemic stroke: 20-50 ml in 200-300 ml of the main solution intravenously drip daily for 1 week, then 10-20 ml intravenously drip - 2 weeks.

Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the main solution intraarterially or intravenously daily treatment duration of about 4 weeks.

Wound healing: 10 ml intravenously or 5 ml intramuscularly daily or 3-4 times a week, depending on the healing process (in addition to topical treatment with Actovegin in topical dosage forms).

Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy: the average dose is 5 ml intravenously daily during intervals of radiation exposure.

Radiation cystitis: daily 10 ml transurethrally in combination with antibiotic therapy.

Side effects of

Allergic reactions:

skin rash

skin hyperemia

hyperthermia, up to anaphylactic shock.

Drug Interaction

Currently unknown.

However, to avoid possible pharmaceutical incompatibilities, it is not recommended to add other drugs to the Aktovegin® infusion solution.

Storage conditions

At a temperature not exceeding 25 РC in a dark place. Store in a place out of reach of children!

Expiration date

3 years

Deystvuyushtee substance

Deproteinizirovann y gemoderivat Resurrection facturer

drugstore

drugstore

Dosage form

injection for injection

Prescribing

Prescribing

Prescribing by the doctor as prescribed by the doctor, For adults p187froof718 as prescribed by the doctor, For adults d187f5

Prescribing

Pregnant as prescribed by a doctor, For adults as prescribed by a doctor

Sendzu19 pharmacyf8519af6161 yes GmbH, Austria, Russia